Rezolute (RZLT) to Release Earnings on Wednesday

Rezolute (NASDAQ:RZLT - Get Free Report) is expected to be issuing its Q3 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). On average, analysts expect Rezolute to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rezolute Trading Up 6.4%

RZLT traded up $0.23 during trading on Monday, reaching $3.80. 866,358 shares of the company were exchanged, compared to its average volume of 630,588. The stock has a market cap of $230.03 million, a P/E ratio of -3.11 and a beta of 1.01. The firm has a 50 day moving average of $3.24 and a 200 day moving average of $4.28. Rezolute has a 52 week low of $2.22 and a 52 week high of $6.19.

Insider Activity

In other news, CFO Daron Evans acquired 10,000 shares of the business's stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the acquisition, the chief financial officer now directly owns 237,900 shares in the company, valued at $687,531. This represents a 4.39% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Nevan C. Elam acquired 12,302 shares of the business's stock in a transaction dated Thursday, March 27th. The stock was purchased at an average price of $2.85 per share, with a total value of $35,060.70. Following the acquisition, the chief executive officer now owns 224,119 shares of the company's stock, valued at approximately $638,739.15. This trade represents a 5.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 39,060 shares of company stock worth $130,694 over the last 90 days. 18.39% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Rezolute

An institutional investor recently bought a new position in Rezolute stock. Goldman Sachs Group Inc. bought a new stake in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 236,209 shares of the company's stock, valued at approximately $685,000. Goldman Sachs Group Inc. owned about 0.39% of Rezolute as of its most recent SEC filing. Institutional investors and hedge funds own 82.97% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. HC Wainwright reiterated a "buy" rating and set a $14.00 price target on shares of Rezolute in a research report on Monday, April 28th. Wedbush reiterated an "outperform" rating and set a $12.00 price target on shares of Rezolute in a research report on Wednesday, May 14th. Guggenheim reiterated a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Finally, JMP Securities boosted their price target on Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Rezolute presently has a consensus rating of "Buy" and an average target price of $12.14.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.